Healthcare AI Market Poised for Explosive Growth as New Technologies Emerge

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

The article continued: Analysts at market.us are predicting the Generative AI in Healthcare Market to reach US$17.2 billion by 2032, growing at a CAGR of 37% along the way. Researchers at Technavio see an even bigger future, projecting the Smart Healthcare Market (including telemedicine, mHealth, smart pills, and AI) to grow by US$125.7 billion through to 2028. Avant Technologies and Ainnova Secure Advanced AI Algorithms for Early Detection of Four Additional Diseases in the U.S. Avant Technologies, Inc. (OTCQB: AVAI), an emerging technology company developing solutions in artificial intelligence in healthcare, today announced its partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on revolutionizing early disease detection using AI, has acquired an exclusive license for 4 groundbreaking, AI-driven algorithms from one of Asia's most respected and largest healthcare institutions. These solutions, validated across diverse geographies, ethnicities, and socio-economic populations with data from over 2-million patients, will join Ainnova's existing diabetic retinopathy and retinal disease detection solutions. The 4 algorithms include early detection for cardiovascular risk, prediabetes and type 2 diabetes, fatty liver disease, and chronic kidney disease. Combined with Ainnova's existing retinal disease detection tools, these new algorithms will be used with Ainnova's powerful cutting-edge AI platform, VisionAI, to detect the early markers of these diseases quickly and accurately by applying AI. The acquisition of an exclusive license to use 4 advanced algorithms in the Americas offers Ainova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, a robust platform for primary care providers to streamline early risk screening and improve patient care in the United States. Ainnova will introduce these cutting-edge solutions in Latin America with strategic partners in primary healthcare services across key markets like Mexico and Brazil. AAC expects to build on Ainnova's regional expansion by securing clearance from the U.S. Food and Drug Administration (FDA) in 2025 to then introduce these solutions in the U.S. market. "This license represents a pivotal moment for Ainnova and for its partnership with Avant as it allows us to bring world class, validated solutions to the Americas," said Vinicio Vargas, CEO of Ainnova. "This effort not only complements our current solutions, but it also aligns with our ongoing R&D initiatives to continue incorporating new diseases that can be detected quickly and affordably, pushing the boundaries of preventive care, and making healthcare more inclusive and accessible to all." CONTINUED... Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ Other recent industry developments and happenings in the market include: Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a clinical-stage biotechnology company that recently combined with Exscientia, recently reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. REC-617 was well-tolerated across all dose levels (2-20 mg QD and 1 mg BID), with most adverse events being mild (Grade 1-2) and reversible. Notably, one patient with metastatic, platinum-resistant ovarian cancer achieved a confirmed durable partial response lasting over 6 months, while four others experienced stable disease for up to 6 months. "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer, Recursion. "Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, recently announced the launch of new AI-enabled capabilities to enhance its Virtual Sitter solution to improve patient safety, address workforce challenges, and enhance care delivery for hospitals and health systems. Teladoc Health's Virtual Sitter uses AI to allow a single remote staff member to monitor more patients, boosting inpatient team capacity by 25%. This innovation complements Teladoc's connected care solutions, including virtual nursing, physician consults, and interpretive services, reducing administrative burdens and improving satisfaction for both clinicians and patients. "For more than a decade, we've pioneered new ways for technology to support human interaction in patient care, helping hospitals and health systems transform care delivery and meet their most pressing challenges," said Andy Puterbaugh, Teladoc Health President of Hospitals and Health Systems. "New applications of AI are now accelerating our impact, supporting continuous improvement of our fully integrated suite of connected care solutions, including Virtual Sitter." Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, in partnership with HeartFocus, a revolutionary, AI-enabled heart echo software by data-driven medtech company, recently announced the launch of the HeartFocus Education app. The HeartFocus Education app uses AI-powered, self-paced learning to help healthcare practitioners master 10 essential cardiac views with clinical accuracy in hours. Officially launched at ANCC MagPath 2024, the app integrates seamlessly with Butterfly iQ3 and iQ+ probes on iOS iPads, offering an intuitive, engaging, and high-impact training experience enhanced by gamification. "HeartFocus is set to make a big impact in cardiac care, and we're thrilled to partner with DESKi on this pioneering education platform," said Darius Shahida, Chief Strategy Officer at Butterfly Network. "By combining our cutting-edge ultrasound technology with HeartFocus' AI-powered training, we're breaking down barriers to cardiac care, empowering more practitioners to learn how to deliver critical diagnostics on the spot." Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, recently announced updates and progress across its internal pipeline of proprietary Drug Creation programs, as well as new breakthroughs demonstrated by Absci's AI Integrated Drug Creation™ platform. Absci leadership and a series of distinguished guest speakers will be presenting on these updates today at Absci's 2024 R&D Day. "We are excited to showcase the target and significant opportunities we see for ABS-201, present new data for ABS-101 and ABS-301, and introduce ABS-501 to our pipeline. ABS-201, a potential treatment for male and female pattern hair loss, represents an opportunity to unlock an entirely new category of therapy for a substantial consumer-driven market with significant clinical unmet need," said Sean McClain, Founder and CEO of Absci. "And as we near the end of 2024, we see next year as an opportunity to reach multiple milestones across our internal portfolio, and maintain a robust pipeline of potential partners across the Pharma and broader healthcare industry landscape." Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content:https://www.prnewswire.com/news-releases/healthcare-ai-adoption-accelerates-as-industry-eyes-125-billion-growth-by-2028-302354609.html

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 - Avant Technologies (OTC:AVAI), Absci (NASDAQ:ABSI)

USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 17, 2025 /PRNewswire/ -- According to experts, soon the integration of artificial intelligence (AI) into healthcare will drastically shift from a novelty, to a critical resource. With over 800 FDA-cleared health AI applications, the new expectation is that AI will be a game changer. In a new article from Fast Company, the author predicts health AI in 2025 will include home testing, AI agents, passive monitoring, ambient documentation, and autonomous coding. The World Economic Forum is also highlighting the ways generative AI could transform clinical trials. According to a new survey from eClinicalWorks, 90% of healthcare professionals report a favorable view of AI. Working to provide these powerful AI tools to the health industry are several innovators, including new developments from Avant Technologies, Inc. AVAI, Recursion Pharmaceuticals, Inc. RXRX, Teladoc Health, Inc. TDOC, Butterfly Network, Inc. BFLY, and Absci Corporation ABSI. The article continued: Analysts at market.us are predicting the Generative AI in Healthcare Market to reach US$17.2 billion by 2032, growing at a CAGR of 37% along the way. Researchers at Technavio see an even bigger future, projecting the Smart Healthcare Market (including telemedicine, mHealth, smart pills, and AI) to grow by US$125.7 billion through to 2028. Avant Technologies and Ainnova Secure Advanced AI Algorithms for Early Detection of Four Additional Diseases in the U.S. Avant Technologies, Inc. AVAI, an emerging technology company developing solutions in artificial intelligence in healthcare, today announced its partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on revolutionizing early disease detection using AI, has acquired an exclusive license for 4 groundbreaking, AI-driven algorithms from one of Asia's most respected and largest healthcare institutions. These solutions, validated across diverse geographies, ethnicities, and socio-economic populations with data from over 2-million patients, will join Ainnova's existing diabetic retinopathy and retinal disease detection solutions. The 4 algorithms include early detection for cardiovascular risk, prediabetes and type 2 diabetes, fatty liver disease, and chronic kidney disease. Combined with Ainnova's existing retinal disease detection tools, these new algorithms will be used with Ainnova's powerful cutting-edge AI platform, VisionAI, to detect the early markers of these diseases quickly and accurately by applying AI. The acquisition of an exclusive license to use 4 advanced algorithms in the Americas offers Ainova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, a robust platform for primary care providers to streamline early risk screening and improve patient care in the United States. Ainnova will introduce these cutting-edge solutions in Latin America with strategic partners in primary healthcare services across key markets like Mexico and Brazil. AAC expects to build on Ainnova's regional expansion by securing clearance from the U.S. Food and Drug Administration (FDA) in 2025 to then introduce these solutions in the U.S. market. "This license represents a pivotal moment for Ainnova and for its partnership with Avant as it allows us to bring world class, validated solutions to the Americas," said Vinicio Vargas, CEO of Ainnova. "This effort not only complements our current solutions, but it also aligns with our ongoing R&D initiatives to continue incorporating new diseases that can be detected quickly and affordably, pushing the boundaries of preventive care, and making healthcare more inclusive and accessible to all." CONTINUED... Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ Other recent industry developments and happenings in the market include: Recursion Pharmaceuticals, Inc. RXRX, a clinical-stage biotechnology company that recently combined with Exscientia, recently reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. REC-617 was well-tolerated across all dose levels (2-20 mg QD and 1 mg BID), with most adverse events being mild (Grade 1-2) and reversible. Notably, one patient with metastatic, platinum-resistant ovarian cancer achieved a confirmed durable partial response lasting over 6 months, while four others experienced stable disease for up to 6 months. "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer, Recursion. "Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." Teladoc Health, Inc. TDOC, the global leader in virtual care, recently announced the launch of new AI-enabled capabilities to enhance its Virtual Sitter solution to improve patient safety, address workforce challenges, and enhance care delivery for hospitals and health systems. Teladoc Health's Virtual Sitter uses AI to allow a single remote staff member to monitor more patients, boosting inpatient team capacity by 25%. This innovation complements Teladoc's connected care solutions, including virtual nursing, physician consults, and interpretive services, reducing administrative burdens and improving satisfaction for both clinicians and patients. "For more than a decade, we've pioneered new ways for technology to support human interaction in patient care, helping hospitals and health systems transform care delivery and meet their most pressing challenges," said Andy Puterbaugh, Teladoc Health President of Hospitals and Health Systems. "New applications of AI are now accelerating our impact, supporting continuous improvement of our fully integrated suite of connected care solutions, including Virtual Sitter." Butterfly Network, Inc. BFLY, a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, in partnership with HeartFocus, a revolutionary, AI-enabled heart echo software by data-driven medtech company, recently announced the launch of the HeartFocus Education app. The HeartFocus Education app uses AI-powered, self-paced learning to help healthcare practitioners master 10 essential cardiac views with clinical accuracy in hours. Officially launched at ANCC MagPath 2024, the app integrates seamlessly with Butterfly iQ3 and iQ+ probes on iOS iPads, offering an intuitive, engaging, and high-impact training experience enhanced by gamification. "HeartFocus is set to make a big impact in cardiac care, and we're thrilled to partner with DESKi on this pioneering education platform," said Darius Shahida, Chief Strategy Officer at Butterfly Network. "By combining our cutting-edge ultrasound technology with HeartFocus' AI-powered training, we're breaking down barriers to cardiac care, empowering more practitioners to learn how to deliver critical diagnostics on the spot." Absci Corporation ABSI, a data-first generative AI drug creation company, recently announced updates and progress across its internal pipeline of proprietary Drug Creation programs, as well as new breakthroughs demonstrated by Absci's AI Integrated Drug Creation™ platform. Absci leadership and a series of distinguished guest speakers will be presenting on these updates today at Absci's 2024 R&D Day. "We are excited to showcase the target and significant opportunities we see for ABS-201, present new data for ABS-101 and ABS-301, and introduce ABS-501 to our pipeline. ABS-201, a potential treatment for male and female pattern hair loss, represents an opportunity to unlock an entirely new category of therapy for a substantial consumer-driven market with significant clinical unmet need," said Sean McClain, Founder and CEO of Absci. "And as we near the end of 2024, we see next year as an opportunity to reach multiple milestones across our internal portfolio, and maintain a robust pipeline of potential partners across the Pharma and broader healthcare industry landscape." Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content:https://www.prnewswire.com/news-releases/healthcare-ai-adoption-accelerates-as-industry-eyes-125-billion-growth-by-2028-302354609.html SOURCE USA News Group ABSIAbsci Corp$2.893.21%WatchlistOverviewAVAIAvant Technologies Inc$0.560020.4%BFLYButterfly Network Inc$3.63-6.44%RXRXRecursion Pharmaceuticals Inc$6.582.81%TDOCTeladoc Health Inc$9.12-0.44%Market News and Data brought to you by Benzinga APIs

How Growing Number of Industries are Leveraging Artificial Intelligence to Create Lucrative Revenue Opportunities - Avant Technologies (OTC:AVAI), C3.ai (NYSE:AI)

FN Media Group News Commentary PALM BEACH, Fla., Jan. 17, 2025 /PRNewswire/ -- The healthcare industry is rapidly integrating artificial intelligence (AI)-powered solutions in various verticals to achieve higher operational & clinical outcomes, which is a key contributing factor to the growth of the global market. According to a report from Grand View Research said that the artificial intelligence in diagnostics market size is projected to grow at a compound annual growth rate (CAGR) of 24.60% through 2030 overburdened healthcare systems struggling with the rapidly rising global prevalence of chronic diseases are driving the demand for automated, innovative processes. Furthermore, the shortage of care providers is contributing to the growing demand for AI-powered systems. The report said: "The ongoing COVID-19 pandemic exposed the shortcomings of the existing healthcare system and accelerated the adoption of digital technologies, such as AI in diagnostics, to accurately analyze complex datasets, thereby, reducing the burden of administrative & operational tasks on clinicians. The emergence of startups and growing recognition in form of funding & investments boosted the market growth. Healthcare startups rapidly began adopting AI-powered systems and receive recognition in the form of favorable government support and funding from private investors & venture capitalists." Active companies active in the markets include: Avant Technologies Inc. AVAI, C3.ai, Inc. AI, SoundHound AI, Inc. SOUN, Nukkleus, Inc. NUKK, Palantir Technologies Inc. PLTR. Grand View Research continued: "Advancements in healthcare IT infrastructure and regular technological developments in cloud storage, computer processing, and machine learning algorithms are supporting the integration of AI-powered systems in diagnostics to provide efficient & accurate diagnosis allowing care providers to devise timely & adequate treatment plans. Pathology and radiology services are witnessing a widespread adoption of AI-based algorithms. For example, AI-powered radiology solutions can collect multiple datasets from imaging modalities and accurately analyze them from the radiologist. Furthermore, several research studies on AI integration in pathology are being conducted and some of the studies are on chronic kidney disease & kidney function tests, and metastatic breast cancer detection. Key participants are focusing on innovating solutions to deliver an accurate and rapid diagnosis of chronic diseases... Key market players are focusing on their product development strategies to expand their portfolios. Furthermore, key participants are devising their collaborations and mergers & acquisition strategies to gain a competitive edge in the market and expand their business." Avant Technologies, Inc. AVAI and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases - Avant Technologies, Inc. ("Avant" or the "Company") and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), announced that Ainnova has started the process of implementing the 4 advanced AI-driven algorithms the company acquired last month into its state-of-the-art Vision AI platform. During the implementation, Ainnova will configure the APIs within its platform, update the functionalities, and then test the new groundbreaking algorithms on a demo population group. The demo group will offer valuable feedback ahead of the Vision AI platform being introduced in several commercial pilot programs in Latin America with strategic partners in primary healthcare services across key markets in the region, including with two major pharmaceutical companies in Costa Rica and in Mexico, and in partnership with several pharmacy chains equipped with labs on site throughout Mexico. The 4 algorithms include early detection for cardiovascular risk, prediabetes and type 2 diabetes, fatty liver disease, and chronic kidney disease. Combined with Ainnova's existing retinal disease detection tools, these new algorithms will be used with Ainnova's Vision AI to detect the early markers of these diseases quickly and accurately by applying AI. Ainnova's Chief Executive Officer, Vinicio Vargas, said, "Patients with chronic conditions face a variety of complications. The ability to screen these individuals in basic health services or during routine primary care check-ups, using fast, non-invasive tests powered by AI, is transformative. Such technology enables highly accurate and timely detection of potential risks or issues, which ensures that patients are referred efficiently to the appropriate specialist. This approach has the potential to significantly enhance patient outcomes and streamline healthcare processes." The acquisition of an exclusive license to use 4 advanced algorithms in the Americas from one of Asia's most respected and largest healthcare institutions, offers Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, a robust platform for primary care providers to streamline early risk screening and improving patient care throughout the Americas. AAC expects to build on Ainnova's regional expansion by securing clearance from the U.S. Food and Drug Administration in 2025 to then introduce these solutions in the U.S. market. CONTINUED... Read this and more news for Avant Technologies at: https://www.financialnewsmedia.com/news-avai/ In other industry developments and happenings in the market recently include: C3.ai, Inc. AI, the Enterprise AI application software company, and Capgemini, a global leader in business and technology transformation, recently announced an expansion of their partnership. This partnership is designed to accelerate and enhance the delivery of Enterprise AI solutions across industries to help clients realize significant benefits including improved efficiency, productivity, and cost reduction. This partnership combines the power of C3 AI's Enterprise AI applications with Capgemini's deep industry expertise and proven global implementation capabilities and capacity. Together, the two companies will deliver Enterprise AI solutions tailored to specific industries including life sciences, energy, utilities, government, banking, and manufacturing. To drive this partnership extension, Capgemini will expand its dedicated C3 AI global practice, focused on delivering Enterprise AI solutions to joint clients across industries at scale, with rapid time to value. SoundHound AI, Inc. SOUN, a global leader in voice artificial intelligence, recently unveiled the first ever in-vehicle voice commerce platform with a demo at CES 2025. The platform, which allows drivers and passengers to order takeout for pick-up directly from the car's infotainment system, will be showcased in SoundHound's CES booth at the Las Vegas Convention Center (West Hall Level 1, Booth #4964, Vehicle Tech & Advanced Mobility). CES attendees will be able to try the new groundbreaking AI software firsthand - with the ability to experiment with in-vehicle ordering from a range of restaurants integrated into SoundHound's platform. Nukkleus, Inc. NUKK announced this week that it has been notified on Jan.15, 2025 that it has regained compliance with the market value of listed securities requirement as outlined in Nasdaq Listing Rule 5450(b)(2)(A) and the market value of publicly held shares requirement as outlined in Nasdaq Listing Rule 5450(b)(2&3)(C). As a result, Nasdaq has officially canceled the hearing scheduled for January 21, 2025, confirming that Nukkleus's securities will continue to be listed and traded on The Nasdaq Stock Market. This milestone highlights Nukkleus's commitment to meeting Nasdaq's rigorous compliance standards and maintaining its position as a publicly traded entity. The management of the company believes this milestone underscores its effective resolution of all compliance matters with Nasdaq, allowing the Company to continue its pursuit of sustainable growth and deliver lasting value to its stakeholders. Pray.com, the number one app for daily prayer and faith-based content, recently partnered with Palantir Technologies Inc. PLTR, a leading builder of artificial intelligence systems, aiming to accelerate new product launches -- especially in the area of language translation -- which could greatly enhance content offerings while exponentially reducing time and costs. Early on, Pray.com recognized the challenges of translating its content into multiple languages, especially when it came to the cost of staffing and idioms. Pray.com sought software to automate the manual and costly process with a system built and tested for scale. Using Palantir's Ontology Software Development Kit (OSDK), Pray.com has finally been able to process transcripts and translations content at the quality of native language speakers. About FN Media Group: At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today's emerging companies. #tickertagpressreleases #pressreleases Follow us on Facebook to receive the latest news updates: https://www.facebook.com/financialnewsmedia Follow us on Twitter for real time Market News: https://twitter.com/FNMgroup Follow us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/ DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty nine hundred dollars for news coverage of the current press releases issued by Avant Technologies, Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. Contact Information: Media Contact email: editor@financialnewsmedia.com - +1(561)325-8757 View original content:https://www.prnewswire.com/news-releases/how-growing-number-of-industries-are-leveraging-artificial-intelligence-to-create-lucrative-revenue-opportunities-302354365.html SOURCE FN Media Group Market News and Data brought to you by Benzinga APIs